Effects of Vitamin K on Matrix Metalloproteinase-3 and Rheumatoid Factor in Women
with Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled Trial.
Author(s): Shishavan NG(1), Gargari BP, Kolahi S, Hajialilo M, Jafarabadi MA, Javadzadeh Y.
Affiliation(s): Author information:
(1)a Department of Biochemistry and Diet Therapy, Nutrition Research Center,
Faculty of Nutrition , Tabriz University of Medical Sciences , Tabriz , IRAN.
Publication date & source: 2015, J Am Coll Nutr. ,
OBJECTIVES: Rheumatoid arthritis (RA) is an autoimmune disease characterized by
an increase in some autoantibodies and proteolytic enzymes, leading to joint
destruction. Although recent investigations have considered vitamin K as an
anti-inflammatory nutrient with an important role in bone metabolism, there is
currently limited information on its efficacy in RA. We aimed to examine the
effects of vitamin K1 (phylloquinone) on the biomarker of joint destruction and
autoantibody in patients with RA.
MATERIALS AND METHODS: This was a randomized clinical trial in which 64 women
with RA who fulfilled the eligibility criteria were randomly allocated to an
intervention or a control group. Vitamin K1 or placebo was administered to the
participants for 8 weeks. Baseline characteristics and anthropometric measures
were obtained. Clinical status using disease activity score in 28 joints
(DAS-28), serum levels of matrix metalloproteinase-3 (MMP-3), and rheumatoid
factor (RF) were assessed before and after the intervention.
RESULTS: The serum level of MMP-3 compared with the baseline values did not
change significantly in the groups. However, the serum concentration of RF
decreased significantly in the vitamin K1 group (p = 0.041). Intergroup
comparison showed no significant change in RF serum level after adjusting for
relevant confounders (p > 0.05).
CONCLUSIONS: Vitamin K1 supplementation at 10 mg/day for 8 weeks did not alter
joint destruction and immune status in the patients with RA compared with the
controls.
|